Effect of lysine side chain length on histone lysine acetyltransferase catalysis

Proietti, Giordano; Wang, Yali; Rainone, Giorgio; Mecinović, Jasmin

Published in:
Scientific Reports

DOI:
10.1038/s41598-020-69510-0

Publication date:
2020

Document version
Final published version

Document license
CC BY

Citation for published version (APA):
Proietti, G., Wang, Y., Rainone, G., & Mecinović, J. (2020). Effect of lysine side chain length on histone lysine acetyltransferase catalysis. Scientific Reports, 10, [13046]. https://doi.org/10.1038/s41598-020-69510-0

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:
• You may download this work for personal use only.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying this open access version
If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 27. Apr. 2021
Effect of lysine side chain length on histone lysine acetyltransferase catalysis

Giordano Proietti1,2, Yali Wang2,3, Giorgio Rainone1 & Jasmin Mecinović1,2*

Histone lysine acetyltransferase (KAT)-catalyzed acetylation of lysine residues in histone tails plays a key role in regulating gene expression in eukaryotes. Here, we examined the role of lysine side chain length in the catalytic activity of human KATs by incorporating shorter and longer lysine analogs into synthetic histone H3 and H4 peptides. The enzymatic activity of MOF, PCAF and GCN5 acetyltransferases towards histone peptides bearing lysine analogs was evaluated using MALDI-TOF MS assays. Our results demonstrate that human KAT enzymes have an ability to catalyze an efficient acetylation of longer lysine analogs, whereas shorter lysine analogs are not substrates for KATs. Kinetics analyses showed that lysine is a superior KAT substrate to its analogs with altered chain length, implying that lysine has an optimal chain length for KAT-catalyzed acetylation reaction.
which is highly conserved among the GNAT and MYST families, or aspartic acid in the case of p300, to date different catalytic mechanisms have been proposed among KATs. The GNAT family members were found to catalyze a direct acetyl transfer from the AcCoA cosubstrate to the nucleophilic \( \text{N}^{\varepsilon} \)-amino group of lysine upon constitution of a ternary complex comprising of KAT-AcCoA-Histone. Members of the MYST family are instead reckoned to catalyze acetylation of histone substrates through a ping-pong mechanism. Combined crystallographic, kinetics, mutagenesis and thermodynamic evidences support that the acetyl transfer mechanism in MYST enzymes is mediated via the formation of the S-acetylated cysteine intermediate in the catalytic pocket that upon reaction with lysine produces the acetyllysine product. Although several KAT crystal structures have been determined, only a few examples include ternary complexes with both histone substrates and AcCoA cosubstrate (or CoASH product), contributing to a limited understanding of KATs' catalytic properties (PDB ID: 2P0W and 1QSN).

Due to their indisputable importance in tuning gene expression, not surprisingly many KATs have been found overexpressed and/or dysregulated in several human pathologies, such as cancer, inflammation, and neurodegenerative disorders. In the past decade, several inhibitors targeting this biomedically important family of epigenetic enzymes have been developed, many of them lacking inter and intra families selectivity as well as displaying poor activity. Given the challenges encountered in the development of KATs inhibitors, a better understanding of the substrate scope for KAT catalysis is of great biomolecular and medicinal interest. Exploring the substrate and cosubstrate specificity of KAT-catalyzed reactions is an important tool that can provide valuable information for the rational design of new inhibitors. Towards this aim, extensive work has been carried out to unravel the specificity of the AcCoA cosubstrate in KAT catalysis. KATs have been found to catalyze the transfer of sterically more demanding acyl moieties, including propionyl, crotonyl, and butyryl, both in vivo and in vitro, from their respective acyl CoA cosubstrate, with differences in cosubstrate acceptance.

Figure 1. (a) KAT-catalyzed histone lysine acetylation and KDAC-catalyzed histone lysine deacetylation; (b) View on HAT1 acetyltransferase (blue) complexed with AcCoA (pink) and H4K12 (green) (PDB: 2P0W); (c) View on tGCN5 acetyltransferase (yellow) complexed with CoASH (blue) and H3K14 (magenta) (PDB: 1QSN).
were incorporated into the key positions of H3 and H4 peptides by SPPS (Fig. 3b,c). Synthetic histone peptides 1–15, sequence: ARTKQTAR as well as a click-based labelling procedure for the detection of KATs substrates, employing synthetic CoA sur-
rogates and engineered KATs37–39. Although in the recent years the investigation of epigenetic enzymes’ suscep-
tibility towards lysine chemical modification gathered great attentions, especially with regards to histone lysine methytransferases (KMTs), histone lysine demethylases (KDMs) and KDACs, we are currently lacking basic molecular knowledge in the context of histone lysine acetylation40–47. Enzyme kinetics showed p300 catalytic efficiency towards a collection of Lys analogs; a synthetic H4K8 peptide was found to be the preferred substrate, followed by D-Lys and γ-thiahomolysine that showed very poor catalytic efficiency48. More recently, γ-thialysine was demonstrated to be efficiently accepted by a panel of human KATs for the transfer of acetyl, propionyl and butyryl moieties from their respective acyl CoA cosubstrates49. To provide a better insight into the role of lysine side chain on histone acetylation, this study is aimed at understanding of the relevance of lysine side chain length on human KAT catalysis.

Results and Discussion

To investigate the role of the length of lysine’s side chain on human KAT catalysis, a panel of histone peptides bearing lysine analogs that differ in the chain length was developed via Fmoc-based Solid-Phase Peptide Synthesis (SPPS) (Fig. 2). While several unnatural lysine analogs with shorter and longer side chain are commercially avail-
able (Dab = two carbons; Orn = three carbons; Lys; hLys = five carbons), novel longer analogs were synthesized in three steps employing a cross-metathesis synthetic strategy (Fig. 3a). Hoveyda-Grubbs II generation catalyst was employed to perform the coupling of Fmoc-allylglycine with synthetic diBoc-protected amino alkenes of variable alkyl chain lengths. The resulting cis/trans mixture was subsequently reduced by hydrogenation in the presence of Pd/C to yield the desired Fmoc-protected lysine analogs (Fig. 3a). Three different human KATs were selected and expressed in E. coli: (i) MOF (KAT8), a member of the MYST family, which preferentially catalyzes acetylation of K16 on the histone H4 tail; and (ii) GCN5 (KAT2A) and PCAF (KAT2B), members of the GNAT family, which predominantly catalyze acetylation of K14 and secondarily of K9 on the histone H3 tail50,51. To obtain interpretable data, we decided to exclude secondary sites of acetylation from the histone H3 peptide sequence. Therefore, we employed a truncated 15-mer H4 peptide (residues 13–27, sequence: GGA RHRKVLRDNIQ) as a reference sequence to study MOF-catalyzed acetylation of H4K16, and two different 15-mer H3 peptides, with alternatively synthetically acetylated K9 and K14 on H3 peptide, to investigate the acetylation of both sites by GCN5 and PCAF (residues 3–17, sequence: TKQTARcK6STGGKacA; residues 1–15, sequence: ARTKQTARcK6STGGKacA). Fmoc-protected lysine analogs containing a modified chain length were incorporated into the key positions of H3 and H4 peptides by SPPS (Fig. 3b,c). Synthetic histone peptides were purified by RP-HPLC, and their identity and purity were assessed by ESI–MS and analytical HPLC (Sup-
plementary Table 1 and Supplementary Figs. 1–24).

MALDI-TOF MS enzymatic assays were carried out to investigate KAT-catalyzed acetylation of synthetic histone peptides. The enzymatic activity of the recombinantly expressed human KATs was measured at different time points (2 µM KAT enzyme, 100 µM histone peptide, 300 µM AcCoA, buffer: 50 mM HEPES, 0.1 mM EDTA, 1 mM DTT, pH = 8.0, 37 °C, hereafter used as standard conditions) (Fig. 3b,c). MOF catalyzed full acetylation of H4K16 in 30 min, whereas GCN5 and PCAF catalyzed quantitative acetylation of H3K14 in 15 min and H3K9 only after 2–3 h (Fig. 4b, h and Supplementary Figs. 25–28). It is noteworthy that diacetylation of histone peptides was not detected under our assay conditions, due to preacetylation of the secondary site on H3. Three control experiments in the absence of KAT and AcCoA showed no acetylation within detection limits, confirming the dependence of the acetylation reaction on the KAT enzymes and AcCoA (Supplementary Figs. 26–28). As further control, H4 and H3 peptides containing stereochemically inverted D-lysine were synthesized. MALDI-TOF data revealed that histones bearing D-lysine are not substrates for our panel of KAT enzymes under standard condi-
tions (Supplementary Figs. 29–33). These findings demonstrate that the lysine’s L-stereochemistry is an essential chemical prerequisite for MOF, GCN5 and PCAF catalysis. Interestingly, p300, one of the most promiscuous KATs, has been observed to catalyze acetylation of the H4K8 histone peptide containing D-Lys (D-H4K8)46. Kinetics data showed that D-H4K8 has a very poor catalytic efficiency relative to H4K8 (76-fold drop in V/K with respect to the H4K8 peptide), a result that may lay in the marked structural differences between p300 and the other KAT families39. In a broader context, D-Lys has been found to be a very poor substrate for functionally

Figure 2. A panel of lysine analogs possessing a different side chain length.

![NH2](image1.png)

Dab | Orn | Lys | hLys | h2Lys | h3Lys | h4Lys
---|---|---|---|---|---|---
![NH2](image2.png) | ![NH2](image3.png) | ![NH2](image4.png) | ![NH2](image5.png) | ![NH2](image6.png) | ![NH2](image7.png) | ![NH2](image8.png)
related human KMTs, where traces of methylation were detected occasionally upon increased reaction times and enzyme concentrations.

We next examined the capacity of human KAT enzymes to catalyze acetylation of unnatural lysine analogs under standard conditions. Histone peptides bearing shorter lysine analogs, Dab and Orn, did not undergo acetylation under standard conditions with MOF, PCAF, and GCN5, at primary and secondary sites of acetylation (Fig. 4a,g and Supplementary Figs. 34–41). In contrast, we observed KAT-catalyzed acetylation of longer side chain analogs (hK, h2K, h3K), though in different degrees among the three enzymes. MOF-catalyzed acetylation of H4hK16 and H4h2K16 was found to be almost quantitative (95% and 90%) after 3 h (Fig. 4c,d). On the other hand, GCN5/PCAF catalytic activity towards the same analogs was generally found reduced. Acetylation of the H3hK14 peptide led to a formation of 83% of H3hK14ac by PCAF and 62% of H3hK14ac by GCN5 after 3 h (Fig. 4i, Supplementary Fig. 42), whereas the H3h2K14 peptide was found to be less efficiently acetylated after 3 h (55% by PCAF and 25% by GCN5) (Fig. 4j, Supplementary Fig. 43). Following the same pattern shown for H3K14, the unnatural analogs introduced at position 9 of H3 underwent less efficient acetylation in the presence of PCAF and GCN5. After 3 h, PCAF and GCN5 were only able to catalyze partial acetylation of H3hK9, producing 50% and 30% of H3hK9ac, respectively (Supplementary Figs. 44–45), whereas the H3hK9 peptide was acetylated to a lesser degree (33% and 14%; Supplementary Figs. 46–47). For all three KATs, h3K-containing histone peptides were observed to be very poor substrates, with conversion as low as 12% for MOF after 3 h (Fig. 4e), and traces (<5%) for PCAF (Fig. 4k) and GCN5 at H3K14 (Supplementary Fig. 48). No acetylation was observed within limits of detection for the H3h3K9 peptide in the presence of PCAF and GCN5. After 3 h, PCAF and GCN5 were only able to catalyze partial acetylation of H3hK9, producing 50% and 30% of H3hK9ac, respectively (Supplementary Figs. 44–45), whereas the H3hK9 peptide was acetylated to a lesser degree (33% and 14%; Supplementary Figs. 46–47). For all three KATs, h3K-containing histone peptides were observed to be very poor substrates, with conversion as low as 12% for MOF after 3 h (Fig. 4e), and traces (<5%) for PCAF (Fig. 4k) and GCN5 at H3K14 (Supplementary Fig. 48). No acetylation was observed within limits of detection for the H3hK9 peptide in the presence of PCAF and GCN5 (Supplementary Figs. 49–50). Interestingly, no acetylation of h3K-containing peptides was detected either with MOF (Fig. 4f), PCAF (Fig. 4i and Supplementary Fig. 51) or GCN5 (Supplementary Figs. 52–53) on H4 and H3, establishing the maximal lysine side chain length to be suitable for KAT catalysis to seven carbons. Our results on KAT-catalyzed acetylation of lysine analogs possessing extended side chains provide an interesting finding. Firstly, to date the only longer lysine analog found to be acetylated by p300 has been γ-thiahomolysine, which differs from the fully carbon-based homologous hLys in basicity, side-chain angle and bond length. Secondly, the extremely stringent chain length requirements regulating the activity of other lysine-modifying epigenetic enzymes, such as KMTs and KDACs, are not a prerequisite for KAT enzymes. In this context, trimethyllysine-binding epigenetic reader proteins appear to tolerate the alterations of the side chain length to a higher degree than the enzymes that install the methyl group on lysine.

To further assess MOF, GCN5 and PCAF substrate specificity towards our library of histone peptides possessing lysine and its longer side chain analogs, MALDI-based kinetics investigations were carried out under steady-state conditions. Kinetic analysis of bi-substrate enzymes, such as KATs, is reckoned to be challenging...
and dependent on many factors. Firstly, given the nature of these enzymes, the binding of one of the two substrates directly influences the binding of the other (with a direct effect on the Michaelis–Menten parameter $K_m$). Secondly, as suggested by Wapenaar and Dekker, the catalytic mechanism of KATs seems to be dependent on the nature of the enzyme construct (whether catalytic domain, full-length or belonging to multi-subunit complexes), as in the case for ESA1, which displayed a ternary complex mechanism when integrated in the piccolo NuA4 complex, and the characteristic cysteine mediated ping-pong mechanism when ESA1 catalytic domain alone was employed$^{24,53,54}$. Therefore, to obtain data that would allow us to directly compare the catalytic properties of the selected KATs towards our selection of histone peptides bearing lysine analogs with longer side chains, two strategies to standardize our kinetic evaluation were taken: i) all the experiments were carried out with the same saturating concentrations of AcCoA and ii) only KATs catalytic domains were employed in the study. Overall, the unnatural lysine analogs exhibited a decreased catalytic activity when compared to their natural counterparts, with decreasing $k_{cat}$ values at the insertion of any additional carbon on lysine side chain (Table 1). Evaluation of MOF kinetic properties revealed that lysine is approximately a 50 times better substrate than its side-chain extended analogs (Table 1). In the case of the H4hK16 peptide, the drop in the catalytic efficiency ($k_{cat}/K_m$) can be attributable to the only decrease of $k_{cat}$ values, due to the display of comparable $K_m$ values with H4K16. Interestingly, H4h2K16 is a comparable substrate to H4hK16, with very similar $k_{cat}/K_m$ values. The result seems to not depend on the number of turnovers of MOF, which are found decreased, in line with the general trend, but rather because of H4h2K16’s more favourable binding affinity – as reflected in fourfold lower $K_m$ values. PCAF and GCN5 kinetic analysis revealed that $K_m$ values generally remained conserved among the peptides’ series, implying a similar binding affinity (Table 1). In contrast, $k_{cat}$ values decreased substantially with an increase of

Figure 4. MALDI-TOF MS data showing (a–f) MOF (2 μM)-catalyzed acetylation of H4K*16 histone peptides (100 μM) and (g–l) PCAF (2 μM)-catalyzed acetylation of H3K*14 histone peptides (100 μM) containing lysine analogs in the presence of AcCoA cosubstrate (300 μM); Overlaid MS spectra of KAT-catalyzed reactions (red) and no enzyme control reactions (black) that were quenched after 3 h incubation at 37 °C.
The side chain length, both in the K14 and K9 peptide series, and for both PCAF and GCN5 (Table 1). This finding, combined with the conserved Km values, revealed that the resulting drops in kcat/Km values towards the side chain extended lysine analogs were mainly a result of a reduced turnover rate. Inserting one carbon (H3hK14) and two carbons (H3h2K14) into the lysine side chain caused kcat/Km decreases of 354- and 890-fold for GCN5, and 263- and 625-fold for PCAF, compared to the acetylation of the H3K14 sequence.

Examination of the secondary site of acetylation (H3K9) revealed a different trend, where H3hK9 and H3h2K9 were found to be more comparable but still poorer substrates to H3K9, with a 15- and 30-fold drop in kcat/Km values, respectively, for PCAF and 263- and 625-fold for GCN5-catalyzed acetylation of H3hK9. A significant decrease in catalytic efficiency may be the result of substrates clashing in the active site, driven by the loss of a catalytically required water molecule. Previous work showed that GCN5 preferentially acetylates K14 over K9 in wild-type histone 3 with a (kcat/Km)K14/KmK9 ratio of 57. In our study the analysis of H3 substrate selectivity yielded (kcat/Km)K14/KmK9 values 43 for PCAF and 177 for GCN5.

Next, we proceeded by investigating the potential inhibitory activity of the histone peptides that did not act as KAT substrates. For practical reasons peptides bearing D-Lys and h3Lys analogs were not included in the evaluation, due to overlapping of MS signals with the respective natural peptide and acetylated product. Therefore, only histone peptides containing Dab, Orn and h4Lys were employed in this experiment. To our purpose, we carried out a single-point screening assay, by incubating an equimolar amount (100 µM) of the H4K16/H3K14/H3K9 peptides and the potential inhibitor peptides containing lysine analogs, and quenching the reactions after 1 h at 37 °C. MS analyses revealed that all tested peptides were not able to significantly inhibit KATs. In all experiments the presence of the unnatural histone peptides did not influence the catalytic properties of the enzymes (Supplementary Figs. 54–58), whose residual activity was found to be always greater than 50% when compared to the positive control consisting of the same reaction in the absence of an inhibitor peptide (Fig. 5). From these findings it can be concluded that IC50 values of histone peptide inhibitors are > 100 µM. A possible explanation of the discovered low inhibitory ability of histone peptides may lay in the low binding affinity (as reflected in high Km values) showed in the enzyme kinetics experiments, which translates into the requirement of higher concentration of the peptides to appreciate competitive inhibition.

**Conclusion**

Our combined synthetic and enzymatic investigations demonstrate that histone lysine acetyltransferases are special enzymes of the epigenetic machinery that have a capacity to acetylate histone peptides bearing lysine analogs with extended side chain. In line with their well-documented ability to catalyze the transfer of bulkier acyl moieties from their respective acyl CoA cosubstrates, human KATs showed an additional degree of substrate promiscuity by less efficiently accepting as substrates histone peptides bearing lysine analogs with longer side chains. Acetyltransferases MOF, PCAF and GCN5 were observed to catalyze the acetylation of lysine analogs bearing up to 7 carbons in the chain length (hK, h3K and h4K), both in primary and secondary sites of acetylation. Interestingly, none of the shorter (Dab, Orn) analogs, D-Lys or the longest lysine analog in our panel (h3K) were found as KAT substrates, indicating that although KATs alleged substrate promiscuity, the active site dynamics in KATs are still governed by stringent structural prerequisites. We further showed that the development of histone peptide based competitive inhibitors for KATs may suffer of lack of potency due to the relatively low binding affinities of these peptides towards KATs. Overall, this study shows that human KAT enzymes do have a broader substrate scope, as demonstrated by their capacity to catalyze acetylation of lysine analogs with longer side chain length. We believe that a better understanding of KAT catalysis, as demonstrated by basic molecular investigations on the substrate scope and biocatalytic potential reported here, provides an important knowledge for examination of posttranslational modifications of histone proteins and for rational drug design, targeting biomedically important KAT enzymes.

### Table 1. Kinetics parameters for KAT-catalyzed acetylation of H4K16, H3K14 and H3K9 histone peptides.

| Enzyme | Peptide | kcat | Km | kcat/Km |
|--------|---------|------|----|---------|
| MOF    | H4K16   | 23.10 ± 1.0 | 593 ± 86 | 38.9  |
|        | H4hK16  | 0.27 ± 0.1   | 343 ± 79 | 0.8   |
|        | H4h2K16 | 0.06 ± 0.01  | 82.2 ± 15 | 0.7   |
| PCAF   | H3K14   | 164 ± 1.2    | 727 ± 95 | 500   |
|        | H3hK14  | 0.93 ± 0.2   | 487 ± 98 | 1.9   |
|        | H3h2K14 | 0.5 ± 0.1    | 606 ± 96 | 1.0   |
|        | H3K9    | 2.75 ± 0.2   | 234 ± 35 | 11.7  |
|        | H3hK9   | 0.21 ± 0.01  | 269 ± 54 | 0.8   |
|        | H3h2K9  | 0.07 ± 0.01  | 179 ± 37 | 4.4   |
| GCN5   | H3K14   | 354 ± 2.1    | 995 ± 198 | 356  |
|        | H3hK14  | 0.87 ± 0.1   | 878 ± 157 | 1.0  |
|        | H3h2K14 | 0.40 ± 0.1   | 1,051 ± 226 | 0.4 |
|        | H3K9    | 3.81 ± 0.5   | 1910 ± 202 | 2.0  |
|        | H3hK9   | 0.76 ± 0.2   | 1624 ± 157 | 0.5  |
Methods

Synthesis and purification of histone peptides. All the histone peptides were manually synthesized employing standard Fmoc-SPPS chemistry on a 0.05 mmol scale on Wang resing (0.87 g/mmol loading capacity, 100–200 mesh). Upon standard amino acid (3.0 eq) activation with HOBt (3.6 eq) and DIC (3.3 eq) in DMF (final volume 2 mL, mixed for 2 min), the mixture was added to the Fmoc-deprotected growing peptide, and coupling reactions were carried out at room temperature for 2 h. Incorporation of newly synthesized amino acids (1.3 eq) were performed overnight at room temperature, with HOBt (1.56 eq) and DIC (1.43 eq). Fmoc deprotection was achieved by swelling the peptide in a solution of 20% piperidine in DMF (v/v), for 20 min. The qualitative Kaiser Test was employed to monitor the accomplishment of both coupling and deprotection steps. DMF washes (bubbling 3 × 2 min with N₂) followed every deprotection and coupling steps. After the incorporation of the last amino acid, the peptides were Fmoc deprotected, dried over Et₂O and cleaved off the resin employing a 95% TFA, 2.5% TIPS, 2.5% MQ cocktail for 4 h. After that the crude peptides were precipitated on cold Et₂O (−20 °C), lyophilised and purified by preparative HPLC on a Phenomenex Gemini-NX 3u C18 110Å reversed-phase column (150 × 21.2 mm) with a flow rate of 10 mL/min at 30 °C. The eluent system constituted of a multistep gradient of Solvent B (0.1% TFA in CH₃CN) in Solvent A (0.1% TFA in MQ water). Two different 30 min methods were used to purify the peptides: Method A) for H3 sequences: 0–3 min (3%), 3–15 min (3–15%), 15–20 min (15–30%), 20–22 min (30–100%), 22–25 (100%), 25–27 min (100–3%) and 27–30 min (3%) for re-equilibration of the column. Method B) for H4 sequences: 0–3 min (3%), 3–15 min (3–20%), 15–20 min (20–35%), 20–22 min (35–100%), 22–25 (100%), 25–27 min (100–3%) and 27–30 min (3%) for re-equilibration of the column. The pure fractions were combined and freeze-dried overnight to yield the target histone peptides as white-off fluffy solids. The purity of the synthesized peptides was then assessed via MALDI TOF–MS, ESI–MS and analytical traces were monitored at 215 nm on a Phenomenex Gemini 5 µm C18 110 Å LC column at a flow rate of 1 mL/min.

Expression and purification of KATs. MOF. Plasmid carrying recombinant His-tagged Human MOF catalytic domain (residues 125–458 in pET19b) was gently provided by Professor Frank J. Dekker (University of Groningen). The protein was expressed and purified as previously described²³. Briefly, E. coli BL21(DE3) cells enriched with human His-tagged MOF WT plasmid, were cultured in LB growth media supplemented with 50 µg/mL ampicillin at 37 °C, to an OD₆₀₀ of 0.6, upon which expression was induced by addition of IPTG (0.3 mM final) and followed by incubation at 20 °C overnight. Harvested cells were pelleted and re-suspended into 10 mM Tris pH 7.4, 750 mM NaCl, 1% glycerol, 1 mM β-ME lysis buffer in presence of protease inhibitor cocktail (Roche) and lysate by sonication. The supernatant was incubated with Ni–NTA beads for 2 h at 4 °C. The beads were loaded on a gravity flow column and washed with 50 mM imidazole in lysis buffer. Subsequently, the protein was eluted with 10 mM MES, 750 mM NaCl, 10 mM Mg citrate, 250 mM imidazole, 1 mM β-ME, 1% glycerol, pH 6.5 and concentrated with a 30 kDa spinfilter device (AMICON, 30 MWCO). The protein was furtherly purified by size-exclusion chromatography (SEC) using the AKTA system, employing a Superdex 200 column equilibrated with 10 mM MES, 750 mM NaCl, 10 mM MgCitrate, 1 mM β-ME, 1% glycerol pH 6.5 at 0.5 mL/min flow speed and purity of the eluted protein was assessed with SDS-page. Pure fractions were pooled, rapidly flash-frozen and stored at -80 °C.

PCAF. Plasmid carrying recombinant SNAP-His-tagged Human PCAF catalytic domain (residues 498–658 in pET16b vector) was gently provided by Professor Milan Mrksich (Northwestern University). The protein was

Figure 5. Enzymes’ residual activity upon incubation of MOF (0.2 µM), PCAF (0.5 µM) or GCN5 (0.5 µM) with H4K*16 (MOF) or H3K*14/H3K*9 (PCAF and GCN5) histone peptides.
expressed as it follows: *E. coli* BL21(DE3) cells were cultured with hPCAF plasmid, were cultured in 2xYT growth media supplemented with 100 µg/mL carbenicillin at 37 °C, to an OD600 of 0.6, upon which expression was induced by addition of IPTG (0.5 mM final) and followed by incubation at 16 °C overnight. Harvested cells were pelleted and re-suspended into 50 mM Tris pH 8.5, 200 mM NaCl, 50 mM imidazole, 5 mM β-ME. Subsequently, the protein was eluted with 50 mM Tris pH 8.5, 200 mM NaCl, 300 mM imidazole, 5 mM β-ME and concentrated using a 30 kDa spinfilter device (AMICON, 30 MWCO). The protein was furtherly purified by size-exclusion chromatography (SEC) using the AKTA system, employing a Superdex 75 column equilibrated with 50 mM Tris pH 8.0, 200 mM NaCl, 1 mM DTT at 0.5 mL/min flow speed. The purity of the eluted protein was assessed with SDS-page. Pure fractions were pooled, rapidly flash-frozen and stored at -80 °C.

**GCN5.** Plasmid carrying recombinant His-tagged Human GCN5 catalytic domain (residues 497–662 in pET28a-LIC vector) was purchased from Addgene (25,482). The protein was expressed and purified as previously described[56]. Briefly, *E. coli* BL21(DE3) cells enriched with hGCN5 WT plasmid were cultured in TB growth media supplemented with 50 µg/mL kanamycin at 37 °C to an OD600 of 0.6, upon which expression was induced by addition of IPTG (0.5 mM final) and followed by incubation at 16 °C overnight. Harvested cells were pelleted and re-suspended into 50 mM NaHPO4 pH 7.5, 500 mM NaCl, 5% glycerol, 1 mM β-ME lysis buffer in presence of protease inhibitor cocktail (Roche, Basel, Switzerland) and lysate by sonication. The supernatant was incubated with Ni–NTA beads for 2 h at 4 °C. The beads were loaded on a gravity flow column and washed with 50 mM Tris pH 8.5, 200 mM NaCl, 50 mM imidazole, 5 mM β-ME. Subsequently, the protein was eluted with 50 mM Tris–NaOH pH 7.5, 500 mM NaCl, 5% glycerol, 1 mM β-ME lysis buffer in presence of protease inhibitor cocktail (Roche, Basel, Switzerland) and lysate by sonication. The supernatant was incubated with Ni–NTA beads for 2 h at 4 °C. The beads were loaded on a gravity flow column and washed with 20 mM HEPES–NaOH pH 7.5, 500 mM NaCl, 50 mM imidazole, 5% glycerol, 1 mM β-ME. Subsequently, the protein was eluted with 20 mM HEPES–NaOH pH 7.5, 500 mM NaCl, 250 mM imidazole, 5% glycerol, 1 mM β-ME and the buffer was exchanged to 20 mM HEPES–NaOH pH 7.5, 150 mM NaCl, 1 mM βME by concentration with a 10 kDa spinfilter device (AMICON, 10 MWCO). Purity of the eluted protein was assessed with SDS-page, and GCN5 was separated in aliquots, rapidly flash-frozen and stored at -80 °C.

**MALDI-TOF MS enzymatic assays.** The KAT enzymatic activity towards histone peptides was measured at different time points under standard conditions (2 µM KAT enzyme, 100 µM peptide, 300 µM AcCoA) in the reaction buffer (50 mM HEPES, 0.1 mM EDTA, 1 mM DTT, pH = 8.0). The reactions were carried out in a final volume of 50 µL and shaken up in a Thermomixer C at 750 rpm, at 37 °C. The reactions were quenched by the addition of TFA 10% in MilliQ water at different time points. All reactions were aliquoted and mixed 1:2 with a solution of α-Cyano-4-hydroxycinnamic acid (CHCCA) in 1:1 MQ and ACN (0.1% TFA) and loaded onto an MTP 384 polished steel target to be analyzed by an UltrafleXtreme-II tandem mass spectrometer (Bruker, Billerica, MA, USA).

**MALDI-TOF MS kinetics assays.** Histone peptides kinetics evaluation was carried out with a MALDI-TOF MS assay under steady-state conditions[57,58]. Histone peptides (1,050–0 µM) were incubated with AcCoA (100 µM) and the reactions were started by the addition of the enzyme (MOF 570 nM, PCAF and GCN5 50 nM) in a final volume of 20 µL in kinetic buffer (50 mM HEPES, 0.1 mM EDTA, 0.01% TRITON-X, pH = 7.4). For histone peptides bearing unnatural lysine analogs, higher concentration of enzymes was used (MOF, PCAF and GCN5 2 µM). Steady state conditions were guaranteed by employing saturating concentrations of AcCoA (> 5 × Km value). AcCoA stock solutions in milli-Q water were calibrated with a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA), employing the characteristic molar extinction coefficient ε260nm = 16,400 M−1 cm−1. Reactions were incubated at 37 °C, shaken at 750 rpm and quenched with TFA 10% in milli-Q water at different time points, within linear production of acetylated peptides extrapolated from time-course plots. All reactions were aliquoted and mixed 1:2 with a solution of α-cyano-4-hydroxycinnamic acid (CHCCA) in 1:1 MQ and ACN (0.1% TFA) and loaded onto MTP 384 polished steel target to be analyzed by UltrafleXtreme-II tandem mass spectrometer (Bruker). The amount of acetylated peptide was calculated by integration of the product peak area and divided it by the amount of unacetylated peptide, taking in account all the ionic species, at any concentration points using the FlexAnalysis software. Kinetic values were extrapolated by fitting Vv values (µM of produced peptide per minutes) and histone peptide concentrations to the Michaelis–Menten equation using the GraphPad Prism 5 software. Kinetic experiments were carried out in duplicates and final values are reported as value ± SD.

**Inhibition assays.** Equimolar amount of the natural histone peptide and the histone peptide possessing the unnatural lysine analog (1:1; 100 µM) were incubated in the presence of AcCoA (300 µM) in the reaction buffer (50 mM HEPES, 0.1 mM EDTA, 1 mM DTT, pH = 8.0). The reactions were started by the addition the enzymes MOF (200 nM), PCAF (500 nM) and GCN5 (500 nM), and carried out at 37 °C for 1 h, after which they were quenched by the addition of 10% TFA in MQ and analyzed by MALDI-TOF MS. Every experiment was carried out in triplicates and normalized to the positive control reaction. Data are shown as the mean value ± SEM.

Received: 21 April 2020; Accepted: 13 July 2020
Published online: 03 August 2020
References

1. Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res. 21, 381–395 (2011).
2. Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41–45 (2000).
3. Jensenius, T. & Allis, C. D. Translating the histone code. Science 293, 1074–1080 (2001).
4. Wang, Z. et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat. Genet. 40, 897–903 (2008).
5. Zhao, Y. Lysine benzoylation is a histone mark regulated by SIRT2. Nat. Commun. 9, 3374 (2018).
6. Zhang, D. et al. Metabolic regulation of gene expression by histone lactylation. Nature 574, 575–580 (2019).
7. Tan, M. et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 146, 1016–1028 (2011).
8. Chen, Y. et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol. Cell. Proteomics 6, 812–819 (2007).
9. Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E. & Mann, M. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat. Rev. Mol. Cell Biol. 15, 536–550 (2014).
10. Marmorstein, R. & Zhou, M. M. Writers and readers of histone acetylation: Structure, mechanism, and inhibition. Cold Spring Harb. Perspect. Biol. 6, a018762 (2014).
11. Drzac, A., Myklebust, L. M., Ree, R. & Arnesen, T. The world of protein acetylation. Biochim. Biophys. Acta 1864, 1372–1401 (2016).
12. Bannister, A. J. & Miska, E. A. Regulation of gene expression by transcription factor acetylation. Cell. Mol. Life Sci. 57, 1184–1192 (2000).
13. Lee, D. Y., Hayes, J. J., Pruss, D. & Wolffe, A. P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72, 73–84 (1993).
14. Seto, E. & Yoshida, M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb. Perspect. Biol. 6, a018713 (2014).
15. Josling, G. A., Selvarajah, S. A., Petter, M. & Duffy, M. F. The role of bromodomain proteins in regulating gene expression. Genes 3, 320–343 (2012).
16. Zeng, L. & Zhou, M. M. Bromodomain: an acetyl-lysine binding domain. FEBS Lett. 513, 124–128 (2002).
17. Fiorentino, F., Mai, A. & Rotili, D. Lysine acetyltransferase inhibitors: structure–activity relationships and potential therapeutic implications. Future Med. Chem. 10, 1067–1091 (2018).
18. Sykes, S. M. et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 24, 841–851 (2006).
19. Roth, S. Y., Denu, J. M. & Allis, C. D. Histone Acetyltransferases. Annu. Rev. Biochem. 70, 81–120 (2001).
20. Sternglanz, R. & Schindelin, H. Structure and mechanism of action of the histone acetyltransferase gc5 and similarity to other N-acetyltransferases. Proc. Natl. Acad. Sci. USA 96, 8807–8808 (1999).
21. Tannen, K. G. et al. Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator. J. Biol. Chem. 274, 18157–18160 (1999).
22. Yang, C., Wu, J., Sinha, S. H., Neveu, J. M. & Zheng, Y. G. Autoacetylation of the MYST lysine acetyltransferase MOF protein. J. Biol. Chem. 287, 34917–34926 (2012).
23. Wapenaar, H. et al. Enzyme kinetics and inhibition of histone acetyltransferase KAT8. Eur. J. Med. Chem. 105, 289–296 (2015).
24. Van, Y., Harper, S., Speicher, D. W. & Marmorstein, R. The catalytic mechanism of the ESA1 histone acetyltransferase involves a self-acetylated intermediate. Nat. Struct. Biol. 9, 862–869 (2002).
25. Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10, 457–469 (2010).
26. Avvakumov, N. & Côté, J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 26, 5395–5407 (2007).
27. Selvi, B. R., Cassel, J. C., Kundu, T. K. & Boutilier, A. L. Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases. Biochim. Biophys. Acta 1799, 840–853 (2010).
28. Barnes, P. J., Adcock, I. M. & Ito, K. Histone acetylation and deacetylation: Importance in inflammatory lung diseases. Eur. Respir. J. 25, 532–563 (2005).
29. Baell, J. B. & Miao, W. Histone acetyltransferase inhibitors: where art thou! Future Med. Chem. 8, 1525–1528 (2016).
30. Huang, M., Huang, J., Zheng, Y. & Sun, Q. Histone acetyltransferase inhibitors: an overview in synthesis, structure-activity relation-ship and molecular mechanism. Eur. J. Med. Chem. 178, 259–286 (2019).
31. He, M., Han, Z., Li, J., Hou, M. & Zheng, Y. G. Chemical biology approaches for investigating the functions of lysine acetyltransferases. Angew. Chem. Int. Ed. 57, 1162–1184 (2018).
32. Zhao, S., Zhang, X. & Li, H. Beyond histone acetylation—writing and erasing histone acetylations. Curr. Opin. Struct. Biol. 53, 169–177 (2018).
33. Barnes, C. E., English, D. M. & Cowley, M. S. Acetylation and Co: an expanding repertoire of histone acylations regulates chromatin and transcription. Essays Biochem. 63, 97–107 (2019).
34. Han, Z. et al. Revealing the protein propionylation activity of the histone acetyltransferase MOF (males absent on the first). J. Biol. Chem. 293, 3410–3420 (2018).
35. Leemhuis, H., Packman, L. C., Nightingale, K. P. & Höffelder, F. The human histone acetyltransferase P/CAF is a promiscuous histone propionyltransferase. ChemBioChem 9, 499–503 (2008).
36. Simithy, J. et al. Characterization of histone acetylation links chromatin modifications with metabolism. Nat. Commun. 8, 1141 (2017).
37. Yang, C. et al. Labeling lysine acetyltransferase substrates with engineered enzymes and functionalized cofactor surrogates. J. Am. Chem. Soc. 135, 7791–7794 (2013).
38. Hwang, Y. et al. A selective chemical probe for coenzyme A-requiring enzymes. Angew. Chemie Int. Ed. 46, 7621–7624 (2007).
39. Simon, R. P. et al. Cofactor analogues as active site probes in lysine acetyltransferases. J. Med. Chem. 62, 2582–2597 (2019).
40. Al’ Temimi, A. H. K. et al. γ-Thialysine versus lysine: an insight into the epigenetic methylation of histones. Bioconjugate Chem. 30, 1798–1804 (2019).
41. Al’ Temimi, A. H. K. et al. The nucleophilic amino group of lysine is central for histone lysine methyltransferase catalysis. Commun. Chem. 2, 112 (2019).
42. Al’ Temimi, A. H. K. et al. Lysine possesses the optimal chain length for histone lysine methyltransferase catalysis. Sci. Rep. 7, 1–12 (2017).
43. Al’ Temimi, A. H. K. et al. Examining sterically demanding lysine analogs for histone lysine methyltransferase catalysis. Sci. Rep. 10, 3671 (2020).
44. Al’ Temimi, A. H. K. et al. Methylation of geometrically constrained lysine analogues by histone lysine methyltransferases. Chem. Commun. 56, 3039–3042 (2020).
45. Al’ Temimi, A. H. K. et al. Importance of the main chain of lysine for histone lysine methyltransferase catalysis. Org. Biomol. Chem. 17, 5693–5697 (2019).
46. Janonnak, N., Hirsch, B. M., Pang, Y. & Zhong, W. Substrate specificity of SIRT1-catalyzed lysine Nε-deacetylation reaction probed with the side chain modified Nε-acetyl-lysine analogs. Bioorg. Chem. 38, 17–25 (2010).
47. Hopkinson, R. J. et al. Is ImjC oxygenase catalysis limited to demethylation? Angew. Chemie Int. Ed. 52, 7709–7713 (2013).
48. Thompson, P. R., Kurooka, H., Nakatani, Y. & Cole, P. A. Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J. Biol. Chem. 276, 33721–33729 (2001).
49. Proietti, G., Rainone, G., Hintzen, J. & Mecinovic, J. Exploring the histone acylome through incorporation of γ-thialysine on histone tails. Bioconjugate Chem. 31, 844–851 (2020).
50. Kuo, Y. & Andrews, A. J. Quantitating the specificity and selectivity of Gcn5-mediated acetylation of histone H3. PLoS ONE 8, e54896 (2013).
51. Kuo, M. H. et al. Transcription-linked acetylation by Gcn5p of histones H3 and H4 at specific lysines. Nature 383, 269–272 (1996).
52. Al Temimi, A. H. K. et al. Recognition of shorter and longer trimethyllysine analogues by epigenetic reader proteins. Chem. Commun. 54, 2409–2412 (2018).
53. Wapenaar, H. & Dekker, F. J. Histone acetyltransferases: challenges in targeting bi-substrate enzymes. Clin. Epigenet. 8, 59 (2016).
54. Yan, Y., Barlev, N. A., Haley, R. H., Berger, S. L. & Marmorstein, R. Crystal structure of yeast Esa1 suggests a unified mechanism for catalysis and substrate binding by histone acetyltransferases. Mol. Cell 6, 1195–1205 (2000).
55. Ringel, A. E. & Wolberger, C. Structural basis for acyl-group discrimination by human Gcn5L2. Acta Crystallogr. D Struct. Biol. 72, 841–848 (2016).
56. Schuetz, A. et al. Crystal structure of a binary complex between human GCN5 histone acetyltransferase domain and acetyl coenzyme A. Proteins 407, 403–407 (2007).
57. Guitot, K. et al. Label-free measurement of histone lysine methyltransferases activity by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal. Biochem. 456, 25–31 (2014).
58. Richardson, S. L. et al. A direct, ratiometric, and quantitative MALDI-MS assay for protein methyltransferases and acetyltransferases. Anal. Biochem. 478, 59–64 (2015).

Acknowledgements
This work was financially supported by the European Research Council (ERC Starting Grant, ChemEpi-gen—715691, to J.M.).

Author contributions
J.M. conceived and supervised the project. G.P. synthesized building blocks and histone peptides. G.P. and Y.W. produced proteins. G.P. and G.R. carried out MALDI-TOF MS enzymatic assays. G.P. and J.M. wrote the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-69510-0.

Correspondence and requests for materials should be addressed to J.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020